254 related articles for article (PubMed ID: 27329511)
21. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
[TBL] [Abstract][Full Text] [Related]
22. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
Alabas OA; Mason KJ; Yiu ZZN; Hampton PJ; Reynolds NJ; Owen CM; Bewley A; Laws PM; Warren RB; Lunt M; Smith CH; Griffiths CEM;
Br J Dermatol; 2023 Apr; 188(5):618-627. PubMed ID: 36763783
[TBL] [Abstract][Full Text] [Related]
24. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of systemic treatments for psoriasis in elderly patients.
Piaserico S; Conti A; Lo Console F; De Simone C; Prestinari F; Mazzotta A; Gualdi G; Guarneri C; Borsari S; Cassano N
Acta Derm Venereol; 2014 May; 94(3):293-7. PubMed ID: 24158307
[TBL] [Abstract][Full Text] [Related]
27. Drug survival of biologic therapies for the treatment of psoriasis: Results of Slovenian national registry.
Lunder T; Marko P; Koser Kolar N; Kralj B; Kecelj Leskovec N
Biologicals; 2018 Jul; 54():44-49. PubMed ID: 29706309
[TBL] [Abstract][Full Text] [Related]
28. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
29. [Biologic therapies in the treatment of psoriasis].
Farhi D; Dupin N
Presse Med; 2009 May; 38(5):832-43. PubMed ID: 19282134
[TBL] [Abstract][Full Text] [Related]
30. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies.
Levin AA; Gottlieb AB; Au SC
J Drugs Dermatol; 2014 Jul; 13(7):848-53. PubMed ID: 25007369
[TBL] [Abstract][Full Text] [Related]
31. Combination Use of Systemic Therapies in Psoriasis: Baseline Characteristics from the Corrona Psoriasis Registry.
Bonomo L; Abittan BJ; Hashim PW; Karki C; Mason M; Lebwohl M
J Drugs Dermatol; 2019 Aug; 18(8):731-740. PubMed ID: 31424705
[TBL] [Abstract][Full Text] [Related]
32. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
33. Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE.
Otero ME; van den Reek JM; Seyger MM; van de Kerkhof PC; Kievit W; de Jong EM
Br J Dermatol; 2017 Aug; 177(2):497-504. PubMed ID: 28078672
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
Ahlehoff O; Skov L; Gislason G; Gniadecki R; Iversen L; Bryld LE; Lasthein S; Lindhardsen J; Kristensen SL; Torp-Pedersen C; Hansen PR
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1128-34. PubMed ID: 25303139
[TBL] [Abstract][Full Text] [Related]
36. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
37. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry.
Lluch-Galcerá JJ; Carrascosa JM; González-Quesada A; Rivera-Díaz R; Sahuquillo-Torralba A; Llamas-Velasco M; Gómez-García FJ; Herrera-Acosta E; de la Cueva P; Baniandrés-Rodríguez O; Lopez-Estebaranz JL; Belinchón I; Ferrán M; Mateu A; Rodríguez L; Riera-Monroig J; Abalde-Pintos MT; Carretero G; García-Donoso C; Pujol-Marco C; Del Alcázar E; Santamaría-Domínguez C; Suárez-Pérez JA; Nieto-Benito LM; Ruiz-Genao DP; Salgado-Boquete L; Descalzo MÁ; García-Doval I
Br J Dermatol; 2024 Feb; 190(3):355-363. PubMed ID: 37846976
[TBL] [Abstract][Full Text] [Related]
38. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.
García-Doval I; Pérez-Zafrilla B; Ferrandiz C; Carretero G; Daudén E; de la Cueva P; Gómez-García FJ; Herrera-Ceballos E; Belinchón-Romero I; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Rivera R; Vanaclocha F;
J Dermatolog Treat; 2016; 27(3):203-9. PubMed ID: 26367799
[TBL] [Abstract][Full Text] [Related]
39. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
van den Reek JM; van Lümig PP; Driessen RJ; van de Kerkhof PC; Seyger MM; Kievit W; de Jong EM
Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
[TBL] [Abstract][Full Text] [Related]
40. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry.
Munera-Campos M; Vilar-Alejo J; Rivera R; Carrascosa JM; Daudén E; Herrera-Acosta E; Sahuquillo-Torralba A; Gómez-García FJ; Baniandrés-Rodríguez O; de la Cueva P; López-Estebaranz JL; Belinchón I; Ferran M; Riera-Monroig J; Rodriguez L; Carretero G; García-Donoso C; Ballescá F; Llamas-Velasco M; Herrera-Ceballos E; Pujol-Marco C; Nieto-Benito LM; Ruiz-Genao DP; Alsina M; Descalzo MA; García-Doval I;
J Dermatolog Treat; 2022 Jun; 33(4):2110-2117. PubMed ID: 33913796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
